ClinicalTrials.gg
RecruitingNCT07746505Updated Aug 5, 2026

Remimazolam Versus Midazolam for General Anesthesia Induction in Elderly Patients Undergoing Non-Cardiac Surgery

An observational study in General Anesthesia, Aged and Intraoperative Hypotension, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
65 Years and older
Sex
All
01

Study summary

This prospective observational cohort study evaluates the effectiveness and safety of two benzodiazepine sedatives-remimazolam and midazolam-used for general anesthesia induction in elderly patients (≥65 years) undergoing elective non-cardiac surgery. Elderly patients have reduced organ reserve and altered pharmacokinetics/pharmacodynamics, increasing their susceptibility to anesthesia-related complications such as intraoperative hypotension, delayed emergence, and postoperative delirium. Remimazolam, an ultra-short-acting benzodiazepine metabolized by organ-independent tissue esterases, is hypothesized to offer greater hemodynamic stability, faster recovery, and a more favorable safety profile than midazolam in this vulnerable population. Investigators prospectively observe and collect data without altering routine clinical care; the choice of sedative is made by the attending anesthesiologist according to standard practice. Propensity score methods will be used to reduce confounding by indication.

Read the detailed description

This is a prospective, observational, cohort study. The exposure is the benzodiazepine sedative actually used at induction; patients are grouped as the remimazolam (RM) or midazolam (MZ) cohort based on the clinical record. Induction and maintenance are individualized by the attending anesthesiologist ; investigators only observe and collect data without altering routine care. All patients receive standard monitoring (ECG, SpO₂, non-invasive/invasive blood pressure, end-tidal CO₂, anesthetic depth). Collected data include demographics, medical history and risk factors, medication history, examination and laboratory results, and intraoperative variables (ASA class, surgery type and duration, hypotension, anesthetic and opioid doses, fluid balance, blood loss, transfusion).

02

Conditions studied

  • General Anesthesia
  • Aged
  • Intraoperative Hypotension
  • Anxiety

Browse trials for

Keywords

  • Remimazolam
  • Midazolam
  • Elderly
  • Non-cardiac surgery
  • Anesthesia induction
  • Hemodynamic stability
  • Quality of recovery
03

In context

Anxiety Disorders Unverified

7,216 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 168 across 978 observational studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Elderly patients (≥65 years) scheduled for elective non-cardiac surgery under general anesthesia at a single tertiary center, who receive a benzodiazepine sedative (remimazolam or midazolam) for induction as part of routine clinical care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 65 years or older.
  2. Scheduled for elective non-cardiac surgery under general anesthesia.
  3. physical status I to IV.
  4. Planned airway management with tracheal intubation or a laryngeal mask airway.
  5. Written provided by the participant or the participant's legally authorized representative.

    -

Exclusion criteria

Exclusion Criteria:

  1. Long-term preoperative benzodiazepine use.
  2. Known allergy or to benzodiazepines, flumazenil, opioids, naloxone, or related drugs.
  3. History of drug abuse or alcoholism within the past 2 years.
  4. No preoperative cognitive assessment available.
  5. Preoperative cognitive impairment, defined as a Mini-Mental State 6.Examination score less than 18.

7.Refusal to provide .

-

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1: Remimazolam group (RM)

    Elderly patients who receive remimazolam as the benzodiazepine sedative during general anesthesia induction (final dose and sequence determined individually by the attending anesthesiologist).

  • Cohort 2: Midazolam group (MZ)

    Elderly patients who receive midazolam as the benzodiazepine sedative during general anesthesia induction (final dose and sequence determined individually by the attending anesthesiologist).

06

What researchers measure

Primary outcomes

  1. Intraoperative Hypotension Burden Measured by the Time-Weighted Average of Mean Arterial Pressure (TWA-MAP) Below an Absolute Threshold (<65 mmHg) or a Relative Threshold (>20% Decrease From Baseline)

    Intraoperative hypotension burden was quantified from mean arterial pressure (MAP) recordings obtained from anesthetic induction through the end of surgery (induction and maintenance periods).

    Time frame: From anesthetic induction through the end of surgery (intraoperative period)

Secondary outcomes

  1. Vasoactive drug requirement

    Time frame: Induction period and entire perioperative period Cumulative dose and frequency of vasoactive agents

  2. Time to Extubation

    Time from discontinuation of anesthetics to removal of the endotracheal tube.

    Time frame: During anesthesia emergence

  3. Quality of Recovery at 24 Hours Postoperatively as Assessed by the Quality of Recovery-15 (QoR-15) Questionnaire

    Quality of postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire, a 15-item patient-reported instrument covering physical comfort, physical independence, emotional state, psychological support, and pain. Each item is scored on an 11-point scale from 0 to 10. The total score ranges from 0 to 150, with higher scores indicating better quality of recovery.

    Time frame: 24 hours after surgery

  4. Perioperative Anxiety Assessed by the Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)

    Perioperative anxiety was assessed using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). The HADS-A consists of 7 items, each rated from 0 to 3, yielding a total score ranging from 0 to 21. Higher scores indicate greater anxiety (a worse outcome).

    Time frame: Day of surgery and postoperative day 2

  5. Composite of Major Organ Complications (Postoperative Delirium, Acute Kidney Injury, Stroke, Acute Myocardial Infarction, Pulmonary Infection, In-Hospital All-Cause Mortality, Postoperative Length of Stay, and Unplanned Reoperation)

    postoperative delirium, acute kidney injury, stroke, acute myocardial infarction, or pulmonary infection. Postoperative delirium will be assessed using the Confusion Assessment Method or clinical documentation. Acute kidney injury will be defined according to Kidney Disease: Improving Global Outcomes criteria. Stroke and acute myocardial infarction will be diagnosed based on clinical, laboratory, electrocardiographic, imaging, and medical record evidence. Pulmonary infection will be diagnosed based on clinical symptoms, radiographic findings, laboratory results, and the need for antimicrobial treatment. In-hospital all-cause mortality will also be recorded.

    Time frame: From the end of surgery until hospital discharge, an average of 7 days

  6. Incidence of Anesthesia-Related Adverse Events (Composite)

    The number/proportion of participants experiencing one or more anesthesia-related adverse events during the perioperative period was recorded. Anesthesia-related adverse events included intraoperative awareness and postoperative nausea and vomiting (PONV).

    Time frame: perioperative

  7. Length of Stay in the Post-Anesthesia Care Unit (PACU)

    Length of stay in the post-anesthesia care unit (PACU), defined as the time from PACU admission until the patient meets PACU discharge readiness criteria, measured in minutes.

    Time frame: From PACU admission until PACU discharge readiness, assessed up to 24 hours after surgery

07

Study locations

1 of 1 sites recruiting
  • The Second Affiliated Hospital of Zhejiang University School of Medicin
    Hangzhou, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 411 non-industry observational studies under Anxiety Disorders, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 49. This study's planned 12 months is below that.

Counting every sponsor, half of 439 studies reached it within 19 months; a quarter within 6 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Aug 5, 2026
StartActual
Jun 15, 2026
Primary completionEst.
Jun 16, 2027
CompletionEst.
Jul 15, 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07746505
Responsible party
Sponsor
First posted
Aug 5, 2026
Start date
Jun 15, 2026
Primary completion
Jun 16, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

min Yan, doctor
Contact
zryanmin@zju.edu.cn
+86 13757118632

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion